In lung and colorectal cancer models, CLZ has been found to affect important oncogenic pathways such as PI3K/protein kinase B (Akt) and adenosine monophosphate-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR), leading to tumor suppression. The gene discussed is AKT1; the disease is colorectal cancer.